Skip to main content
Sirona Biochem Corp. logo

Sirona Biochem Corp. — Investor Relations & Filings

Ticker · SRBCF ISIN · CA82967M1005 LEI · 549300CQE1Q87IG6W210 TSXV Real estate activities
Open in API
Filings indexed 367 across all filing types
Latest filing 2025-08-01 Regulatory Filings
Country CA Canada
Listing TSXV SRBCF

About Sirona Biochem Corp.

https://www.sironabiochem.com/

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery firm utilizing a proprietary platform technology to develop novel compounds. Through its wholly-owned French subsidiary, TFChem, the company specializes in stabilizing carbohydrate molecules, often via fluorination chemistry, to enhance their efficacy and safety for medical and cosmetic applications. Sirona Biochem's business strategy involves licensing or selling its patented compounds, such as the anti-aging and anti-wrinkle molecule GlycoProteMim™ (TFC-1326), to leading global pharmaceutical and cosmetic companies in exchange for up-front fees, milestone payments, and ongoing royalties.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings
2025-08-01 English
Statement of executive compensation (form 51-102F6V) - English.pdf
Regulatory Filings
2025-04-24 English
News release - English.pdf
Capital/Financing Update Classification · 92% confidence The document is a press release announcing Sirona Biochem’s non‐brokered private placement offering of unsecured, convertible debentures, detailing the terms, conversion features, use of proceeds, and regulatory approvals required. This is a classic update on the company’s fundraising and capital structure. It is neither an earnings announcement nor a full financial report, but specifically a financing activity notification. Therefore, it falls under the Capital/Financing Update category.
2025-04-22 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing a strategic investment/private placement of CAD 3 million in convertible debentures and a joint‐venture LOI, detailing fundraising terms, use of proceeds, conditions and closing timeline. It is a financing activity update rather than an earnings release, regulatory filing, or report attachment. This clearly fits the Capital/Financing Update category.
2025-04-22 English
News release - English.pdf
Regulatory Filings
2025-01-15 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing the publication of a scientific study on the TFC-1326 compound by Sirona Biochem. It highlights the study's findings, clinical trial results, and includes statements from company leadership. There is no financial data, regulatory filing, or report attached or referenced as being filed. The content focuses on research publication and product development updates rather than financial or governance matters. This type of document is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement that does not fit into other specific categories such as Annual Report, Earnings Release, or Investor Presentation.
2024-11-20 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.